Quest Diagnostics Incorporated (DGX)

In October 2025, Quest Diagnostics reported strong third-quarter financial results, leading to raised guidance for the full year. The company also announced an agreement with Corewell Health to establish a lab services joint venture in Michigan. In January 2026, Quest Diagnostics was named to Fortune's 2026 World's Most Admired Companies list. In early February 2026, Barclays upgraded Quest Diagnostics' stock rating, contributing to positive momentum. The company also launched a novel Flow Cytometry MRD Blood Test for Myeloma in February 2026 and is scheduled to release its fourth-quarter and full-year 2025 financial results on February 10, 2026.

The diagnostic testing and services industry generally benefits from stable demand, driven by factors such as an aging population and increased prevalence of chronic diseases. While the industry experiences stable demand, analysts in late 2025 projected a deceleration in revenue growth for Quest Diagnostics over the next 12 months. However, the company has also reported strong demand for its clinical solutions and growth in consumer-initiated testing. Steady demand for non-urgent surgeries has also contributed to increased demand for diagnostic checkups.

Quest Diagnostics is a leading provider of diagnostic information services, offering a range of clinical laboratory and anatomic pathology testing, and healthcare insights. The company's core business is Diagnostic Information Services, which generates over 95% of its revenue. Quest Diagnostics provides tests across various specialties and offers employer population health services, Quanum health IT solutions, population health tools, and pharmaceutical support. The company's services are delivered to various stakeholders in the healthcare industry.

Quest Diagnostics operates a national network in the United States, including laboratories and patient service centers, serving a significant portion of the adult American population and U.S. healthcare providers. Internationally, Quest Diagnostics has a presence through the Global Diagnostic Network in countries such as Puerto Rico, Mexico, Brazil, and Canada.

Quest Diagnostics has maintained a strong brand reputation, being named to Fortune's World's Most Admired Companies list for the 12th consecutive year. This recognition is based on attributes such as product quality, innovation, long-term value, financial profile, social responsibility, and people management, highlighting the company's sustained positive reputation within the healthcare industry.

Institutional investors hold approximately 60.88% of Quest Diagnostics' stock, with major shareholders including Vanguard Group Inc, BlackRock, Inc., Price T Rowe Associates Inc /md/, State Street Corp, and JPMorgan Chase & Co. Insiders own about 0.42% of the stock, while public companies and individual investors hold approximately 38.70%. As of January 30, 2026, institutional shareholders held 88.06% of the float.